NOVATO

Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference

Retrieved on: 
Tuesday, May 7, 2024
Bank, Conference

NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company's chief medical officer and executive vice president, will participate in a fireside at Bank of America’s 2024 Healthcare Conference on Tuesday, May 14, 2024, at 1:40 p.m. PT.

Key Points: 
  • NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company's chief medical officer and executive vice president, will participate in a fireside at Bank of America’s 2024 Healthcare Conference on Tuesday, May 14, 2024, at 1:40 p.m. PT.
  • The live and archived webcast of the panel will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

Retrieved on: 
Thursday, May 2, 2024
Osteogenesis imperfecta, Burosumab, Patient, OI, Ageing, Ultragenyx

NOVATO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter ended March 31, 2024 and reaffirmed its financial guidance for 2024.

Key Points: 
  • Total operating expenses for the first quarter of 2024 were $274 million, including non-cash stock-based compensation of $37 million.
  • Net cash used in operations for the quarter ended March 31, 2024 was $191 million.
  • For the full year 2024, the company reaffirms:
    Crysvita revenue in the range of $375 million to $400 million.
  • ET to discuss the first quarter 2024 financial results and provide a corporate update.

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

Retrieved on: 
Thursday, April 25, 2024

NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m.

Key Points: 
  • NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m.
  • ET on Thursday, May 2, 2024, to discuss its financial results and corporate update for the quarter ending March 31, 2024.
  • The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations .
  • To participate in the live call, please register by clicking on the following link ( registration link ) and you will be provided with dial-in details.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, April 19, 2024
Employment

NOVATO, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 44,965 restricted stock units of the company’s common stock to 14 newly hired non-executive officers of the company.

Key Points: 
  • NOVATO, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 44,965 restricted stock units of the company’s common stock to 14 newly hired non-executive officers of the company.
  • The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of April 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

Retrieved on: 
Monday, April 15, 2024
Deviance (sociology), American Academy, Attention deficit hyperactivity disorder, Patient, Multi, FAAN, Nature, MDRI, Behavior, Communication, Sleep, Disease, AAN, Neurology, Cohort, ASA, Natural history, Pharmaceutical industry

NOVATO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced new data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome. Patients in Expansion Cohorts A & B treated with a set dose and regimen of GTX-102 showed rapid and clinically meaningful improvement across multiple domains consistent with or exceeding Dose-escalation Cohorts 4-7 data at Day 170. Treatment of the Dose-escalation Cohorts 4-7 showed long-term increasing and sustained clinical benefit far exceeding Natural History data at Day 758. These data will be discussed in more detail in a corporate presentation being hosted by the company today at 8:00 a.m. ET and will also be presented by Kemi Olugemo, M.D., FAAN at the 76th Annual American Academy of Neurology Meeting (AAN) in Denver on Tuesday, April 16.

Key Points: 
  • ET
    NOVATO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced new data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome.
  • Treatment of the Dose-escalation Cohorts 4-7 showed long-term increasing and sustained clinical benefit far exceeding Natural History data at Day 758.
  • Day 170 data were consistent with the treatment benefit observed in the Dose-escalation Cohorts at a similar timepoint.
  • “The totality of these interim data demonstrates that treatment with GTX-102 resulted in rapid, multi-domain improvements that continued during maintenance dosing.

Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome

Retrieved on: 
Friday, April 12, 2024
Conference call, American Academy, AAN, Safety, Neurology, Angelman syndrome

NOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the conference call to discuss new clinical efficacy and safety data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome that will be presented at the American Academy of Neurology Meeting (AAN), will now be taking place on Monday, April 15, 2024 at 8 a.m. Eastern Time (ET). The slides accompanying the call will be shared on company’s website at https://ir.ultragenyx.com/events-presentations before the call.

Key Points: 
  • Conference call now scheduled for Monday, April 15 at 8:00 a.m.
  • ET
    NOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the conference call to discuss new clinical efficacy and safety data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome that will be presented at the American Academy of Neurology Meeting (AAN), will now be taking place on Monday, April 15, 2024 at 8 a.m. Eastern Time (ET).
  • The slides accompanying the call will be shared on company’s website at https://ir.ultragenyx.com/events-presentations before the call.

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

Retrieved on: 
Friday, April 12, 2024
American Academy, Safety, Patient, Angelman syndrome, Abstract (summary), UBE3A, Trial of the century, Science, AAN, Neurology, Ultragenyx, Child

GTX-102 is an investigational antisense oligonucleotide delivered via intrathecal administration and is designed to target and inhibit expression of UBE3A antisense transcript (UBE3A-AS).

Key Points: 
  • GTX-102 is an investigational antisense oligonucleotide delivered via intrathecal administration and is designed to target and inhibit expression of UBE3A antisense transcript (UBE3A-AS).
  • The GTX-102 emerging science presentation will include data beyond what is currently available online.
  • Title: Clinical Activity and Safety of GTX-102, an Investigational Antisense Oligonucleotide for the Treatment of Patients With Angelman Syndrome
    Session: Child Neurology and Developmental Neurology: Neurogenetics 2
    Session: Child Neurology and Developmental Neurology: Neurogenetics 2
    Ultragenyx will host a conference call at 8:00 a.m.
  • ET on Wednesday, April 17, 2024, to discuss the new efficacy and safety data from the GTX-102 Phase 1/2 clinical study being presented at the conference.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 22, 2024
Employment

NOVATO, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 13,020 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company.

Key Points: 
  • NOVATO, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 13,020 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company.
  • The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of March 18, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

Ultragenyx to Participate at Investor Conferences in March

Retrieved on: 
Tuesday, February 27, 2024
Conference, Pharmaceutical industry

NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) --  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management will be participating in three upcoming investor conferences.

Key Points: 
  • NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) --  Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management will be participating in three upcoming investor conferences.
  • 44th Annual Cowen Healthcare Conference (Boston, MA)
    Monday, March 4, 2024, Eric Crombez, M.D., Chief Medical Officer, will participate in a fireside chat and host 1x1 meetings.
  • Leerink Partners Global Biopharma Conference (Miami, FL)
    Tuesday, March 12, 2024, Emil Kakkis, M.D., Ph.D., CEO and President and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1x1 meetings.
  • Barclays 26th Annual Global Healthcare Conference (Miami, FL)
    Wednesday, March 13, 2024, Emil Kakkis and Howard Horn will participate in a fireside chat and host 1x1 meetings.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, February 23, 2024
Employment

NOVATO, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 10,995 restricted stock units of the company’s common stock to nine newly hired non-executive officers of the company.

Key Points: 
  • NOVATO, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 10,995 restricted stock units of the company’s common stock to nine newly hired non-executive officers of the company.
  • The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of February 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.